Literature DB >> 11504748

Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up.

G Gebauer1, T Fehm, E Merkle, E P Beck, N Lang, W Jäger.   

Abstract

PURPOSE: To evaluate the detection of epithelial cells in bone marrow of breast cancer patients as an indicator of metastatic disease. PATIENTS AND METHODS: Between 1989 and 1994, bone marrow biopsies were performed on 393 breast cancer patients during primary surgery. Specimens were stained immunocytochemically for epithelial cells expressing cytokeratins or the epithelial membrane antigen. The long-term outcomes of these patients were analyzed in this study.
RESULTS: In 166 of 393 patients, epithelial cells were found in bone marrow (BM) aspirates. These patients were designated BM+. The rate of tumor recurrence or cancer-related death was significantly higher in BM+ patients than in BM- patients. Multivariate analysis using the Cox regression model revealed BM status as a prognostic parameter independent of tumor size and axillary lymph node status. However, tumor size and axillary lymph node status were clearly superior prognostic parameters.
CONCLUSION: Disseminated epithelial cells in BM are associated with poor clinical outcome in breast cancer patients. However, the presence of these cells is not a sufficient parameter to predict growing metastases in the majority of patients, suggesting that epithelial cells in the BM of breast cancer patients at the time of surgery have limited metastatic potential. The role of these cells needs to be further evaluated.

Entities:  

Mesh:

Year:  2001        PMID: 11504748     DOI: 10.1200/JCO.2001.19.16.3669

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  33 in total

Review 1.  Prognostic factors in breast cancer: current and new predictors of metastasis.

Authors:  D F Hayes; C Isaacs; V Stearns
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

Review 2.  Clinical Relevance of Disseminated Tumor Cells in the Bone Marrow and Circulating Tumor Cells in the Blood of Breast Cancer Patients.

Authors:  Volkmar Müller; Tanja Fehm; Wolfgang Janni; Gerhard Gebauer; Erich Solomayer; Klaus Pantel
Journal:  Breast Care (Basel)       Date:  2009-09-29       Impact factor: 2.860

3.  Disseminated tumor cells are not associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma.

Authors:  Stefan Kommoss; Andreas D Hartkopf; Bernhard Krämer; Anne-Kathrin Bunz; Friederike Grevenkamp; Felix Kommoss; Jana Pasternak; Sabine M Arbabi; Markus Wallwiener; Annette Staebler; Sigurd F Lax; Sara Y Brucker; Florin-Andrei Taran
Journal:  J Cancer Res Clin Oncol       Date:  2017-07-14       Impact factor: 4.553

Review 4.  Circulating Tumor Cells in Early-Stage Breast Cancer.

Authors:  A D Hartkopf; M Banys; N Krawczyk; M Wallwiener; H Schneck; H Neubauer; T Fehm
Journal:  Geburtshilfe Frauenheilkd       Date:  2011-12       Impact factor: 2.915

5.  Monitoring dynamic interactions between breast cancer cells and human bone tissue in a co-culture model.

Authors:  Christopher H Contag; Wen-Rong Lie; Marie C Bammer; Jonathan W Hardy; Tobi L Schmidt; William J Maloney; Bonnie L King
Journal:  Mol Imaging Biol       Date:  2014-04       Impact factor: 3.488

6.  Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients.

Authors:  Christian Schindlbeck; Ulrich Andergassen; Simone Hofmann; Julia Jückstock; Udo Jeschke; Harald Sommer; Klaus Friese; Wolfgang Janni; Brigitte Rack
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-23       Impact factor: 4.553

7.  Expression of human mammaglobin as a marker of bone marrow micrometastasis in breast cancer.

Authors:  Yunjiang Liu; Li Ma; Xianyi Liu; Li Wang
Journal:  Exp Ther Med       Date:  2011-12-22       Impact factor: 2.447

Review 8.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

9.  The controversial clinicobiological role of breast cancer stem cells.

Authors:  Claudia Casarsa; Saro Oriana; Danila Coradini
Journal:  J Oncol       Date:  2009-03-19       Impact factor: 4.375

10.  On the way to specifically targeting minimal residual disease?

Authors:  Gerhard Gebauer
Journal:  Breast Cancer Res       Date:  2008-10-07       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.